Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
Conditions: Eosinophilic Granulomatosis With Polyangiitis; Churg-Strauss Syndrome Interventions: Drug: NS-229; Drug: Placebo Sponsors: NS Pharma, Inc.; Nippon Shinyaku Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials